Table 3 Bivariable associations between low dose dabigatran eligible patients’ characteristics on low or standard dose of dabigatran
|  | Low dose eligible that received low dose Dabigatran (n = 442) | Low dose eligible that received standard dose Dabigatran (n = 959) | P value | Before Matching Standardized Difference | After Matching (N = 366 vs 366) Standardized Difference |
|---|---|---|---|---|---|
Year | Â | Â | 0.001 | Â | Â |
 2010–2012 | 57.7% | 69.3% |  | 0.244 | 0.228 |
 2013 | 16.1% | 10.3% |  | 0.170 | 0.289 |
 2014 | 10.9% | 8.1% |  | 0.093 | 0.047 |
 2015 | 7.7% | 6.5% |  | 0.048 | 0 |
 2016–2017 | 7.7% | 5.7% |  | 0.078 | 0.011 |
Region | Â | Â | 0.1 | Â | Â |
 Midwest | 15.4% | 12.4% |  | 0.086 | 0.008 |
 Northeast | 0.5% | 1.4% |  | 0.096 | 0.141 |
 South | 73.3% | 76.7% |  | 0.080 | 0 |
 West | 10.9% | 9.5% |  | 0.045 | 0.035 |
Age Category |  |  | < 0.001 |  |  |
 65–69 | 7.9% | 14.0% |  | 0.195 | 0 |
 70 to 74 | 16.5% | 24.2% |  | 0.192 | 0 |
 75 to 79 | 18.6% | 28.5% |  | 0.235 | 0 |
 80 to 84 | 25.1% | 19.3% |  | 0.140 | 0 |
 85 to 89 | 13.1% | 7.8% |  | 0.174 | 0 |
 90 or over | 18.8% | 6.3% |  | 0.385 | 0 |
Sex | Â | Â | 0.2 | Â | Â |
 Female | 57.9% | 54.3% |  | 0.072 | 0 |
 Male | 42.1% | 45.7% |  |  |  |
 Race Category |  |  |  |  |  |
 White | 84.2% | 85.0% |  | 0.023 | 0 |
 Black | 10.4% | 8.9% |  | 0.052 | 0 |
 Hispanic | 2.5% | 2.4% |  | 0.006 | 0 |
 Other |  |  |  |  | 0 |
Smoking | Â | Â | 0.04 | Â | Â |
 Yes | 11.5% | 15.7% |  | 0.123 | 0.055 |
 No | 88.5% | 84.3% |  |  |  |
Weight Category (based on ICD-9 and ICD-10 codes for BMI Category) | Â | Â | 0.02 | Â | Â |
 Underweight | 1.6% | 0.6% |  | 0.092 | 0 |
 Healthy or Overweight | 8.6% | 6.3% |  | 0.089 | 0.062 |
 Obese or Severe Obese | 20.4% | 26.3% |  | 0.140 | 0.013 |
 Others | 69.5% | 66.8% |  | 0.056 | 0.024 |
Comorbid Conditions | |||||
 Prior Stroke | 26.7% | 27.4% | 0.8 | 0.016 | 0.042 |
 Prior major bleeding | 29.0% | 28.2% | 0.8 | 0.018 | 0.006 |
 Diabetes | 55.0% | 54.0% | 0.7 | 0.019 | 0.077 |
 Prior AMI | 10.6% | 6.2% | 0.003 | 0.162 | 0.147 |
 Liver Disease | 2.9% | 3.2% | 0.8 | 0.017 | 0 |
 Heart Failure | 56.8% | 40.7% | < 0.001 | 0.327 | 0.265 |
 Hypertension | 98.2% | 96.1% | 0.04 | 0.124 | 0.082 |
 Ischemic cardiomyopathy | 60.4% | 57.2% | 0.3 | 0.064 | 0.089 |
 Pulmonary | 18.8% | 13.3% | 0.008 | 0.148 | 0.066 |
 COPD | 37.8% | 36.2% | 0.6 | 0.033 | 0.034 |
 Transfusion from Procedure | 5.4% | 4.3% | 0.3 | 0.054 | 0.051 |
 Revascularization | 18.6% | 17.8% | 0.7 | 0.019 | 0.043 |
 Implantable Devices | 20.1% | 17.5% | 0.2 | 0.067 | 0 |
 Valve Disease | 45.9% | 42.0% | 0.2 | 0.079 | 0.099 |
Concurrent Drugs (+/− 90 days of initiating DOAC) | |||||
 SSRI/SNRI | 32.6% | 36.5% | 0.15 | 0.083 | 0.023 |
 Strong and moderate p-gp inhibitors | 53.5% | 79.9% | < 0.001 | 0.580 | 0.068 |
 Warfarin | 22.6% | 31.0% | 0.001 | 0.189 | 0.153 |
 Strong p-gp and cyp3a4 dual inhibitors | 35.7% | 47.5% | < 0.001 | 0.241 | 0.089 |
 ACE inhibitors | 74.0% | 72.7% | 0.6 | 0.029 | 0.044 |
 Angiotensin receptor blockers | 46.6% | 45.9% | 0.8 | 0.015 | 0.066 |
 Beta blockers | 95.2% | 92.9% | 0.09 | 0.099 | 0.165 |
 Calcium channel blockers | 69.7% | 67.5% | 0.4 | 0.048 | 0.098 |
 Digoxin | 28.7% | 33.8% | 0.06 | 0.109 | 0.083 |
 Proton pump inhibitors | 64.7% | 63.2% | 0.6 | 0.032 | 0.119 |
 NSAIDs | 52.7% | 55.4% | 0.4 | 0.053 | 0.055 |
 Antiplatelets | 35.3% | 31.3% | 0.13 | 0.085 | 0.099 |
 Insulin | 22.9% | 17.6% | 0.02 | 0.130 | 0.206 |
 Statins | 80.8% | 83.3% | 0.24 | 0.066 | 0.007 |
Renal Disease | |||||
 Moderate (GFR 30–60 ml/min/1.73 m2) | 45.7% | 74.9% | < 0.001 | 0.6245 | 0.0439 |
 Severe (GFR < 30 ml/min/1.73 m2) | 54.3% | 25.1% |  |  |  |